Pancreatic Adenocarcinoma in the Finistere Area, France, Between 2002 and 2011 (1002 Cases) Population Characteristics, Treatment and Survival

被引:7
作者
Arnachellum, Rubeshen Pillay [1 ]
Cariou, Melanie [2 ]
Nousbaum, Jean-Baptiste [1 ,2 ]
Jezequel, Julien [1 ]
Le Reste, Jean Yves [3 ]
Robaszkiewicz, Michel [1 ,2 ]
机构
[1] CHU La Cavale Blanche, Hepatogastroenterol Dept, Blvd Tanguy Prigent, F-29609 Brest, France
[2] CHU Morvan, SPURBO ERCR, Digest Tumors Registry Finistere, Brest, France
[3] Univ Western Brittany, ERCR SPURBO, Dept Gen Practice, Brest, France
关键词
pancreatic adenocarcinoma; epidemiology; therapeutic management; survival; prognostic factors; DUCTAL ADENOCARCINOMA; BILIARY OBSTRUCTION; CANCER; CHEMOTHERAPY; GEMCITABINE; PROGNOSIS; RESECTION;
D O I
10.1097/MPA.0000000000000594
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: The aims of the study were (a) to describe the characteristics of all incident cases of pancreatic adenocarcinoma diagnosed in the population of the Finistere area between 2002 and 2011, (b) to report on their therapeutic management, and (c) to analyze survival and prognostic factors. Methods: All residents of the administrative region of Finistere who were diagnosed with pancreatic adenocarcinoma between January 2002 and December 2011 were registered in the digestive cancer registry. Survival data were analyzed using the Kaplan-Meier method and were compared using log-rank tests. Multivariate analysis was performed using a binary logistic regression model to identify prognostic factors. Results: A total of 1002 patients with a pancreatic adenocarcinoma were registered, of whom 60% had metastases at diagnosis. Only 10% of patients underwent a potentially curative negative margin resection (R0); their median survival was 22.0 months. The median survival of the overall population was 4.1 months. The stages of the disease and the patient's age were independent prognostic factors in multivariate analysis. Conclusions: Our study confirms the dramatic prognosis of this cancer. Because the tumor stage is the main prognostic factor in pancreatic adenocarcinoma, efforts should focus on the earlier diagnosis of pancreatic cancer.
引用
收藏
页码:953 / 960
页数:8
相关论文
共 30 条
[1]  
American Cancer Society, 2012, Cancer Facts Figures 2012
[2]  
[Anonymous], TUM SOL
[3]  
[Anonymous], GASTROENTEROL CLIN B
[4]   Current and future systemic treatment options in metastatic pancreatic cancer [J].
Arslan, Cagatay ;
Yalcin, Suayib .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (04) :280-295
[5]   Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): A retrospective cohort study at the National Center for Tumor Diseases Heidelberg [J].
Berger, Anne Katrin ;
Abel, Ulrich ;
Komander, Christine ;
Harig, Sabine ;
Jaeger, Dirk ;
Springfeld, Christoph .
PANCREATOLOGY, 2014, 14 (03) :211-215
[6]   Prognostic factors related with survival in patients with pancreatic adenocarcinoma [J].
Bilici, Ahmet .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (31) :10802-10812
[7]   National failure to operate on early stage pancreatic cancer [J].
Bilimoria, Karl Y. ;
Bentrem, David J. ;
Ko, Clifford Y. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Talamonti, Mark S. .
ANNALS OF SURGERY, 2007, 246 (02) :173-180
[8]  
Binder-Foucard F, 2013, ESTIMATION NATL INCI
[9]   Managing malignant biliary obstruction in pancreas cancer: Choosing the appropriate strategy [J].
Boulay, Brian R. ;
Parepally, Mayur .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (28) :9345-9353
[10]   Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion? [J].
Buc, E. ;
Couvelard, A. ;
Kwiatkowski, F. ;
Dokmak, S. ;
Ruszniewski, P. ;
Hammel, P. ;
Belghiti, J. ;
Sauvanet, A. .
EJSO, 2014, 40 (11) :1578-1585